Importantly, our findings transcend uricase as a drug and apply to other PEGylated therapeutics that are facing significant PEG‐related challenges in the clinic or that were previously withdrawn from the market due to PEG‐induced severe infusion reactions and anaphylaxis, such as pegasparaginase (Oncospar; Ovation) and peginesatide (Omontys; Affymax and Takeda).[14a] Pegasparaginase is PEGylated asparaginase used in the clinic to treat acute lymphoblastic leukemia. The gene discussed is ASPG; the disease is anaphylaxis.